Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Sederma currently has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. The prosecution of these applications is distributed, involving 5 distinct examiners across 3 distinct art units. This distribution suggests that the company's intellectual property covers a range of sub-specialties within the biotechnology sector, requiring review from multiple technical groups at the patent office. The use of different examiners for the active cases indicates that no single individual is currently overseeing a cluster of the company's filings.
The busiest examiner identified in the data is KELLY-O'NEILL, YOLANDA LYNNETTE, who is managing 1 pending office action. Because each of the 5 distinct examiners is handling a single case, the prosecution risk is spread across the patent office staff. For a practitioner, this means there is no opportunity to leverage a relationship with a single examiner to resolve multiple pending actions. Instead, 3 different art units must be navigated, each potentially having its own internal guidelines and examination culture that could impact the 5 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY-O'NEILL, YOLANDA LYNNETTE | 1 | 31.8% | +23.7% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 48.6% | +78.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287257 | COMPOSITIONS FOR CHEMICAL SYNTHESIS OF PEPTIDES | KELLY-O'NEILL, YOLANDA LYNNETTE | — |
| 18035840 | TETRAPEPTIDES, COMPOSITIONS COMPRISING THEM, AND THEIR COSMETIC USE | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018412 | COSMETIC OR DERMATOLOGICAL PEPTIDE-BASED TREATMENT OF THE SKIN AND ITS INTEGUMENTS | KOMATSU, LI N | 2d overdue |
| 18287257 | COMPOSITIONS FOR CHEMICAL SYNTHESIS OF PEPTIDES | KELLY-O'NEILL, YOLANDA LYNNETTE | — |
| 18035840 | TETRAPEPTIDES, COMPOSITIONS COMPRISING THEM, AND THEIR COSMETIC USE | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 17642581 | N-ACYL-TYROSINE DERIVATIVES AND USES THEREOF | JOHNSON, CHRISTOPHER LINDSAY | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1692 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287257 | COMPOSITIONS FOR CHEMICAL SYNTHESIS OF PEPTIDES | KELLY-O'NEILL, YOLANDA LYNNETTE | 1692 | §102§112 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18035840 | TETRAPEPTIDES, COMPOSITIONS COMPRISING THEM, AND THEIR COSMETIC USE | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §102§112 | Non-Final OA | — | Pending | May 08, 2023 |
| 18018412 | COSMETIC OR DERMATOLOGICAL PEPTIDE-BASED TREATMENT OF THE SKIN AND ITS INTEGUMENTS | KOMATSU, LI N | 1658 | §103 | Final Rejection | 2d overdue | Pending | Jan 27, 2023 |
| 17642581 | N-ACYL-TYROSINE DERIVATIVES AND USES THEREOF | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103 | Final Rejection | — | Pending | Mar 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSederma has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Yolanda Lynnette Kelly-O'Neill has the most, with 1 of Sederma's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
